logo-loader
viewTrutrace Technologies Inc.

Full interview: TruTrace Technologies prepares to start Phase 2 testing of verification pilot program

TruTrace Technologies (CSE: TTT) CEO Robert Galarza joined Steve Darling from Proactive in Toronto to shares new the company, along with with their Partners at Shoppers Drug Mart, is about to begin Phase two testing of the StrainSecure platform.

Galarza talked about another company that will be a part of that. Galarza also told Proactive about their strategic alliance with Deloitte and how key that is for this growing company. 

Quick facts: Trutrace Technologies Inc.

Price: 0.065 CAD

CSE:TTT
Market: CSE
Market Cap: $5.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Trutrace Technologies Inc. named herein, including the promotion by the Company of Trutrace Technologies Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: TruTrace Technologies ready to focus attention on generating...

TruTrace Technologies (CSE: TTT) CEO Robert Galarza joined Steve Darling from Proactive Vancouver with new the company the has completed their beta testing with Shoppers Drug Mart and he talks about what is next.   Galarza also discussed turning his attention to revenue and what markets...

on 01/09/2020

2 min read